A comprehensive development agenda on tenofovir alafenamide in clinical practice

Antonio Di Biagio, Niccolò Riccardi, Stefano Rusconi, Giovanni Guaraldi, Marco Borderi, Andrea De Luca, Nicola Gianotti, Sergio Lo Caputo, Paolo Maggi, Renato Maserati, Franco Maggiolo

Research output: Contribution to journalReview article

Abstract

The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy. Currently available HIV-1 regimens are wide enough to allow diversified usage in different settings. Despite the fact that TAF is not capillary accessible, even in industrialized countries, ultimate International Guidelines have already included TAF in backbone or in single-tablet regimens. Due to a better safety profile, TAF will progressively replace TFV disoproxil fumarate, both in naïve and experienced patients. However, therapeutic innovations have to deal with budget constraints and different global spending-review patterns. The aim of this article is to give a comprehensive agenda of TAF use in naïve and experienced HIV-1 infected patients, providing a full review of the studies present in the literature and contextualizing these findings into daily clinical practice.

Original languageEnglish
Pages (from-to)75-82
Number of pages8
JournalAIDS Reviews
Volume20
Issue number2
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Tenofovir
HIV-1
Budgets
Developed Countries
Tablets
Guidelines
Safety
Therapeutics
GS-7340

Keywords

  • Antiretroviral strategies
  • Combination antiretroviral treatment
  • Tenofovir alafenamide
  • Tenofovir disoproxil fumarate

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Di Biagio, A., Riccardi, N., Rusconi, S., Guaraldi, G., Borderi, M., De Luca, A., ... Maggiolo, F. (2018). A comprehensive development agenda on tenofovir alafenamide in clinical practice. AIDS Reviews, 20(2), 75-82. https://doi.org/10.24875/AIDSRev.M18000017

A comprehensive development agenda on tenofovir alafenamide in clinical practice. / Di Biagio, Antonio; Riccardi, Niccolò; Rusconi, Stefano; Guaraldi, Giovanni; Borderi, Marco; De Luca, Andrea; Gianotti, Nicola; Lo Caputo, Sergio; Maggi, Paolo; Maserati, Renato; Maggiolo, Franco.

In: AIDS Reviews, Vol. 20, No. 2, 01.04.2018, p. 75-82.

Research output: Contribution to journalReview article

Di Biagio, A, Riccardi, N, Rusconi, S, Guaraldi, G, Borderi, M, De Luca, A, Gianotti, N, Lo Caputo, S, Maggi, P, Maserati, R & Maggiolo, F 2018, 'A comprehensive development agenda on tenofovir alafenamide in clinical practice' AIDS Reviews, vol. 20, no. 2, pp. 75-82. https://doi.org/10.24875/AIDSRev.M18000017
Di Biagio, Antonio ; Riccardi, Niccolò ; Rusconi, Stefano ; Guaraldi, Giovanni ; Borderi, Marco ; De Luca, Andrea ; Gianotti, Nicola ; Lo Caputo, Sergio ; Maggi, Paolo ; Maserati, Renato ; Maggiolo, Franco. / A comprehensive development agenda on tenofovir alafenamide in clinical practice. In: AIDS Reviews. 2018 ; Vol. 20, No. 2. pp. 75-82.
@article{1639c9345f634604bce7bdadcbc21879,
title = "A comprehensive development agenda on tenofovir alafenamide in clinical practice",
abstract = "The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy. Currently available HIV-1 regimens are wide enough to allow diversified usage in different settings. Despite the fact that TAF is not capillary accessible, even in industrialized countries, ultimate International Guidelines have already included TAF in backbone or in single-tablet regimens. Due to a better safety profile, TAF will progressively replace TFV disoproxil fumarate, both in na{\"i}ve and experienced patients. However, therapeutic innovations have to deal with budget constraints and different global spending-review patterns. The aim of this article is to give a comprehensive agenda of TAF use in na{\"i}ve and experienced HIV-1 infected patients, providing a full review of the studies present in the literature and contextualizing these findings into daily clinical practice.",
keywords = "Antiretroviral strategies, Combination antiretroviral treatment, Tenofovir alafenamide, Tenofovir disoproxil fumarate",
author = "{Di Biagio}, Antonio and Niccol{\`o} Riccardi and Stefano Rusconi and Giovanni Guaraldi and Marco Borderi and {De Luca}, Andrea and Nicola Gianotti and {Lo Caputo}, Sergio and Paolo Maggi and Renato Maserati and Franco Maggiolo",
year = "2018",
month = "4",
day = "1",
doi = "10.24875/AIDSRev.M18000017",
language = "English",
volume = "20",
pages = "75--82",
journal = "AIDS Reviews",
issn = "1139-6121",
publisher = "Publicaciones Permanyer",
number = "2",

}

TY - JOUR

T1 - A comprehensive development agenda on tenofovir alafenamide in clinical practice

AU - Di Biagio, Antonio

AU - Riccardi, Niccolò

AU - Rusconi, Stefano

AU - Guaraldi, Giovanni

AU - Borderi, Marco

AU - De Luca, Andrea

AU - Gianotti, Nicola

AU - Lo Caputo, Sergio

AU - Maggi, Paolo

AU - Maserati, Renato

AU - Maggiolo, Franco

PY - 2018/4/1

Y1 - 2018/4/1

N2 - The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy. Currently available HIV-1 regimens are wide enough to allow diversified usage in different settings. Despite the fact that TAF is not capillary accessible, even in industrialized countries, ultimate International Guidelines have already included TAF in backbone or in single-tablet regimens. Due to a better safety profile, TAF will progressively replace TFV disoproxil fumarate, both in naïve and experienced patients. However, therapeutic innovations have to deal with budget constraints and different global spending-review patterns. The aim of this article is to give a comprehensive agenda of TAF use in naïve and experienced HIV-1 infected patients, providing a full review of the studies present in the literature and contextualizing these findings into daily clinical practice.

AB - The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy. Currently available HIV-1 regimens are wide enough to allow diversified usage in different settings. Despite the fact that TAF is not capillary accessible, even in industrialized countries, ultimate International Guidelines have already included TAF in backbone or in single-tablet regimens. Due to a better safety profile, TAF will progressively replace TFV disoproxil fumarate, both in naïve and experienced patients. However, therapeutic innovations have to deal with budget constraints and different global spending-review patterns. The aim of this article is to give a comprehensive agenda of TAF use in naïve and experienced HIV-1 infected patients, providing a full review of the studies present in the literature and contextualizing these findings into daily clinical practice.

KW - Antiretroviral strategies

KW - Combination antiretroviral treatment

KW - Tenofovir alafenamide

KW - Tenofovir disoproxil fumarate

UR - http://www.scopus.com/inward/record.url?scp=85049117108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049117108&partnerID=8YFLogxK

U2 - 10.24875/AIDSRev.M18000017

DO - 10.24875/AIDSRev.M18000017

M3 - Review article

VL - 20

SP - 75

EP - 82

JO - AIDS Reviews

JF - AIDS Reviews

SN - 1139-6121

IS - 2

ER -